Molecular signatures of ovarian diseases: Insights from network medicine perspective

Kori M., Gov E., ARĞA K. Y.

SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE, vol.62, no.4, pp.266-282, 2016 (Journal Indexed in SCI) identifier

  • Publication Type: Article / Review
  • Volume: 62 Issue: 4
  • Publication Date: 2016
  • Doi Number: 10.1080/19396368.2016.1197982
  • Page Numbers: pp.266-282
  • Keywords: Ovarian cancer, ovarian endometriosis, polycystic ovarian syndrome, reporter biomolecules, therapeutic targets, TRANSCRIPTION FACTOR, GENE-EXPRESSION, BREAST-CANCER, SIGNALING PATHWAY, CUMULUS CELLS, ASSOCIATION, BIOMARKERS, ENDOMETRIOSIS, METABOLISM, MICRORNAS


Dysfunctions and disorders in the ovary lead to a host of diseases including ovarian cancer, ovarian endometriosis, and polycystic ovarian syndrome (PCOS). Understanding the molecular mechanisms behind ovarian diseases is a great challenge. In the present study, we performed a meta-analysis of transcriptome data for ovarian cancer, ovarian endometriosis, and PCOS, and integrated the information gained from statistical analysis with genome-scale biological networks (protein-protein interaction, transcriptional regulatory, and metabolic). Comparative and integrative analyses yielded reporter biomolecules (genes, proteins, metabolites, transcription factors, and micro-RNAs), and unique or common signatures at protein, metabolism, and transcription regulation levels, which might be beneficial to uncovering the underlying biological mechanisms behind the diseases. These signatures were mostly associated with formation or initiation of cancer development, and pointed out the potential tendency of PCOS and endometriosis to tumorigenesis. Molecules and pathways related to MAPK signaling, cell cycle, and apoptosis were the mutual determinants in the pathogenesis of all three diseases. To our knowledge, this is the first report that screens these diseases from a network medicine perspective. This study provides signatures which could be considered as potential therapeutic targets and/or as medical prognostic biomarkers in further experimental and clinical studies.